Skip to main content

Table 3 Classification of subject IDs with valid re-read data

From: Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries

  Treatment group (randomized and received at least one dose)
Placebo (N = 101) TQ 200 mg (N = 104) MQ 250 mg (N = 101) Total (N = 306)
No. of subjects with valid re-read results 93 100 96 289
No. of subjects with positive smears 31 2 2 35
No. of subjects without positive smears 62 98 94 254
No. of subjects without valid re-read results 8 4 5 17
  1. Valid re-read slides are those with either an outcome of “positive” or “negative” and were collected on or after the 1st dose